Deucravacitinib for scarring hair loss (Phase 2)
Treatments studied
Part of Skin clinical trials.
This study tests an oral medication called deucravacitinib for people with scarring hair loss (frontal fibrosing alopecia or central centrifugal cicatricial alopecia). It aims to see if the drug can reduce inflammation and stop or slow hair loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have had moderate-to-severe frontal fibrosing alopecia or central centrifugal cicatricial alopecia for at least 6 months.
- Your hair loss started less than 5 years ago.
- You have not had a positive TB test or untreated TB.
- You are not pregnant or breastfeeding and use effective birth control if needed.
- You have not used certain hair loss or immune-suppressing medications recently (check with study team).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral medication called delgocitinib, which targets certain enzymes linked to inflammation, in people with central centrifugal cicatricial alopecia (CCCA) or lichen planopilaris (LPP). It aims to see if the drug is safe and if it changes biomarkers (biological signals) related to these conditions.
This trial tests a cream called delgocitinib to see if it can reduce redness and scaling in people with frontal fibrosing alopecia, a type of hair loss. It may help improve your symptoms if other treatments haven't worked.
This Phase 4 study tests whether deucravacitinib can improve psoriasis by correcting abnormal immune-cell signals seen in people with moderate-to-severe disease. It may help reduce symptoms and improve control of psoriasis, while researchers also track immune changes.
This trial tests an investigational oral medication called deucravacitinib for teenagers (adolescents) with moderate to severe plaque psoriasis. It aims to see if the drug is safe and works well.
This trial tests an oral medication called deucravacitinib for people who have both psoriasis and eczema (or psoriasis that looks like eczema) on their skin. The goal is to see if it can help reduce the severity of their plaques and itch.
This study tests a medication called deucravacitinib for adults with rare genetic skin conditions that cause blisters or severe scaling. The goal is to see if it can reduce symptoms safely.
Hear when a new Central Centrifugal Cicatricial Alopecia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.